Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (scFv4-Ig) is an appended IgG format, which includes four scFv moieties at the N-termini of the constant regions. It is a bivalent homodimer, in which one anti-CEA scFv is fused to the CH1 domain of a heavy chain and another anti-DR5 scFv to the CL domain of a light chain, or vice versa. The resulting leads to 2+2 antigen-binding valency. This BsAb can induce targeted apoptosis by activation of the death receptor. It is designed for the research of Breast cancer; Ovary cancer; Colon cancer; Lung cancer therapy.